180 Life Sciences Corp
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| For the Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| Operating Expenses: | ||
| Research and development | $240,905 | $365,186 |
| Research and development - related parties | 135,455 | 170,542 |
| General and administrative | 1,996,608 | 1,556,740 |
| Total Operating Expenses | 2,372,968 | 2,092,468 |
| Loss From Operations | (2,372,968) | (2,092,468) |
| Other Income (Expense): | ||
| Other income | 6,391 | 1,039,364 |
| Interest expense | (2,655) | (16,449) |
| Change in fair value of derivative liabilities | - | (191) |
| Total Other Income (Expense), Net | 3,736 | 1,022,724 |
| Loss Before Income Taxes | (2,369,232) | (1,069,744) |
| Income tax benefit | - | - |
| Net Loss | (2,369,232) | (1,069,744) |
| Other Comprehensive Income (Loss): | ||
| Foreign currency translation adjustments | (64,691) | 6,460 |
| Total Comprehensive Loss | $(2,433,923) | $(1,063,284) |
| Basic and Diluted Net Loss per Common Share | ||
| Basic | $(0.67) | $(1.68) |
| Diluted | $(0.67) | $(1.68) |
| Weighted Average Number of Common Shares Outstanding: | ||
| Basic | 3,539,331 | 638,339 |
| Diluted | 3,539,331 | 638,339 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.